PortfoliosLab logoPortfoliosLab logo
CRSP vs. CMS
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CRSP vs. CMS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and CMS Energy Corporation (CMS). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CRSP achieves a -0.80% return, which is significantly lower than CMS's 4.32% return.


CRSP

1D
-4.00%
1M
0.76%
YTD
-0.80%
6M
0.85%
1Y
40.78%
3Y*
-7.16%
5Y*
-13.88%
10Y*

CMS

1D
1.80%
1M
-4.76%
YTD
4.32%
6M
0.43%
1Y
5.44%
3Y*
10.63%
5Y*
6.13%
10Y*
8.55%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CRSP vs. CMS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRSP
CRISPR Therapeutics AG
-0.80%33.23%-37.12%54.00%-46.36%-50.51%151.39%113.18%21.68%15.89%
CMS
CMS Energy Corporation
4.32%8.13%18.60%-5.21%0.84%9.71%-0.32%30.04%8.25%17.03%

Correlation

The correlation between CRSP and CMS is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.05

Correlation (3Y)
Calculated over the trailing 3-year period

0.08

Correlation (5Y)
Calculated over the trailing 5-year period

0.06

Correlation (All Time)
Calculated using the full available price history since Oct 20, 2016

0.03

Fundamentals

EPS

CRSP:

-$6.24

CMS:

$4.92

PS Ratio

CRSP:

1.15K

CMS:

1.83

Total Revenue (TTM)

CRSP:

$4.10M

CMS:

$8.82B

Gross Profit (TTM)

CRSP:

-$171.17M

CMS:

$4.16B

EBITDA (TTM)

CRSP:

-$509.21M

CMS:

$3.09B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRSP vs. CMS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRSP
CRSP Risk / Return Rank: 6060
Overall Rank
CRSP Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
CRSP Sortino Ratio Rank: 6161
Sortino Ratio Rank
CRSP Omega Ratio Rank: 5858
Omega Ratio Rank
CRSP Calmar Ratio Rank: 6161
Calmar Ratio Rank
CRSP Martin Ratio Rank: 5858
Martin Ratio Rank

CMS
CMS Risk / Return Rank: 4949
Overall Rank
CMS Sharpe Ratio Rank: 5252
Sharpe Ratio Rank
CMS Sortino Ratio Rank: 4343
Sortino Ratio Rank
CMS Omega Ratio Rank: 4242
Omega Ratio Rank
CMS Calmar Ratio Rank: 5252
Calmar Ratio Rank
CMS Martin Ratio Rank: 5454
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRSP vs. CMS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and CMS Energy Corporation (CMS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CRSPCMSDifference

Sharpe ratio

Return per unit of total volatility

0.66

0.35

+0.32

Sortino ratio

Return per unit of downside risk

1.35

0.58

+0.78

Omega ratio

Gain probability vs. loss probability

1.16

1.07

+0.09

Calmar ratio

Return relative to maximum drawdown

1.03

0.49

+0.53

Martin ratio

Return relative to average drawdown

1.75

1.32

+0.42

CRSP vs. CMS - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is 0.66, which is higher than the CMS Sharpe Ratio of 0.35. The chart below compares the historical Sharpe Ratios of CRSP and CMS, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CRSPCMSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.66

0.35

+0.32

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.23

0.33

-0.56

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.42

Sharpe Ratio (All Time)

Calculated using the full available price history

0.23

0.35

-0.12

Drawdowns

CRSP vs. CMS - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, smaller than the maximum CMS drawdown of -91.20%. Use the drawdown chart below to compare losses from any high point for CRSP and CMS.


Loading charts...

Drawdown Indicators


CRSPCMSDifference

Max Drawdown

Largest peak-to-trough decline

-85.11%

-91.20%

+6.09%

Max Drawdown (1Y)

Largest decline over 1 year

-42.25%

-11.02%

-31.23%

Max Drawdown (3Y)

Largest decline over 3 years

-64.91%

-19.61%

-45.30%

Max Drawdown (5Y)

Largest decline over 5 years

-80.68%

-27.56%

-53.12%

Max Drawdown (10Y)

Largest decline over 10 years

-29.55%

Current Drawdown

Current decline from peak

-75.23%

-9.42%

-65.81%

Average Drawdown

Average peak-to-trough decline

-49.16%

-27.36%

-21.80%

Ulcer Index

Depth and duration of drawdowns from previous peaks

24.84%

4.10%

+20.74%

Volatility

CRSP vs. CMS - Volatility Comparison

CRISPR Therapeutics AG (CRSP) has a higher volatility of 15.39% compared to CMS Energy Corporation (CMS) at 5.48%. This indicates that CRSP's price experiences larger fluctuations and is considered to be riskier than CMS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CRSPCMSDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.39%

5.48%

+9.91%

Volatility (6M)

Calculated over the trailing 6-month period

42.57%

12.15%

+30.42%

Volatility (1Y)

Calculated over the trailing 1-year period

61.70%

15.77%

+45.93%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

60.49%

18.93%

+41.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

64.29%

20.67%

+43.62%

Dividends

CRSP vs. CMS - Dividend Comparison

CRSP has not paid dividends to shareholders, while CMS's dividend yield for the trailing twelve months is around 3.10%.


PositionTTM20252024202320222021202020192018201720162015
CMS
CMS Energy Corporation
3.10%3.10%3.09%3.36%3.62%2.67%2.67%2.43%2.88%2.81%2.98%3.22%
CRSP
CRISPR Therapeutics AG
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

CRSP vs. CMS - Financials Comparison

This section allows you to compare key financial metrics between CRISPR Therapeutics AG and CMS Energy Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B20222023202420252026
1.46M
2.73B
(CRSP) Total Revenue
(CMS) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CRSP and CMS have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRSP has higher volatility (15.39%) compared to CMS (5.48%). In terms of maximum drawdown, CRSP dropped -85.11% vs CMS's -91.20%.

CRSP currently has the higher Sharpe Ratio (0.66 vs 0.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CRSP and CMS

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer